ELGN-EYE

N/A

Report date: 2022/11/07 17:05:04

Base Information

Drug NameELGN-EYE
Drug Alias NameELGN-EYE
ClassificationBiologics
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsRetinopathy of Prematurity
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesElgan Pharma Ltd
China Registration ClassN/A

Develop Information

Active CompaniesElgan Pharma Ltd
Inactive CompaniesN/A
Active IndicationsRetinopathy of Prematurity
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A